Glenmark Pharmaceuticals Inc., USA voluntarily recalled Diltiazem Hydrochloride Extended-Release Capsules on Nov. 1, 2024, according to the FDA. The recall addresses cGMP deviations involving an impurity above recommended limits.
How to tell if you have it
- Brand: Glenmark
- Product: Diltiazem Hydrochloride Extended-Release Capsules, USP 90mg
- NDC: 16714-554-01
- Lot #: 17222452, Exp Date 11/30/2024; 17230607, Exp Date 02/28/2025
- Quantity: 4704 bottles
The hazard
The recall is due to cGMP deviations involving the presence of N-nitroso-Desmethyl-Diltiazem impurity above the FDA recommended interim limit.
Context
GovInfoNow's records show Glenmark Pharmaceuticals Inc., USA has 54 other recalls on record since 2017-11-20. Other recent recalls of similar products include Glenmark Azelaic Acid Gel 15% Recall (2026-07-23), Glenmark Alyacen Birth Control Tablets Recall (2026-05-27), and Glenmark Ondansetron Tablets Recall (2025-12-30). Other recent recalls of similar products include Asclemed Duloxetine Capsules Recall (2026-05-14), Breckenridge Duloxetine Capsules Recall (2026-04-21), and Ajanta Pharma Recalls Duloxetine Capsules Due to Nitrosamine Impurity Risk (2026-04-29).